• Mauricio Sarmiento, Javier Díaz, Patricio Rojas, Catherine Gutiérrez, Verónica Jara, Marcela Vidal, James Campbell, María José García, Yorman Flores, Vicente Sandoval, Felipe Palacios, Maximiliano Vergara, Mauricio Ocqueteau, and Francisco Barriga.
• Red UC Christus, Pontificia Universidad Católica de Chile, Santiago, Chile.
• Rev Med Chil. 2024 Sep 1; 152 (9): 960968960-968.

UnlabelledAllogeneic transplantation (HSCT) is a curative option for several hematological diseases. Our center has privileged the use of identical family donors (IFD) or haploidentical (HD) donors. However, the chances of finding family donors may be challenging in small families or unsuitable donors. In these cases, there is the possibility of obtaining hematopoietic precursors from unrelated donors (URD) with complete or almost complete HLA compatibility.Aimthis work analyzes the results of a historical cohort of patients with allogeneic transplantation in our institution.Methodsa retrospective analysis of data base and clinical records of patients with allogeneic transplantation in our adult transplantation program.Resultsbetween 2005 and 2023, 370 TPH were performed, of which 150 were IFD (40%), 167 HD (45%) and 53 URD (15%). The median age of the patients was 37 years (range 16-76), the majority were transplanted for acute leukemia (60%) and 41% were women. With a median follow-up of 8 years, the overall survival was 64, 67, and 65% for IFD, HD or URD. Subgroup analysis showed more severe cases of graft versus host disease in HD group (p= 0.001).Conclusionour experience shows that the results of DNR, DFI, and DFH are similar. 15% of patients were transplanted with URD because of the absence of suitable family donors.

22 keywords...

hide…